No Data
No Data
Inovio Pharmaceuticals' INO-3107 Shows Promising Clinical Trial Results, Earns 'Buy' Rating From Analyst
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)
Express News | Inovio Pharmaceuticals Inc - No Serious Adverse Events Identified in Retrospective Trial
Express News | Inovio Pharmaceuticals Inc - New Data to Inform Re-Dosing Strategy for Rrp Treatment
Express News | New Retrospective Data Shows Half of Rrp Patients Treated With Ino-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
INOVIO Reports Inducement Grant Under Inducement Plan